Virtus ETF Advisers’s ChemoCentryx, Inc. CCXI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-10,074
| Closed | -$520K | – | 487 |
|
|
2022
Q3 | $520K | Buy |
10,074
+144
| +1% | +$5.95K | 0.21% | 208 |
|
|
2022
Q2 | $246K | Sell |
9,930
-1,284
| -11% | -$28.3K | 0.09% | 302 |
|
|
2022
Q1 | $281K | Hold |
11,214
| – | – | 0.13% | 181 |
|
|
2021
Q4 | $408K | Sell |
11,214
-4,928
| -31% | -$173K | 0.15% | 141 |
|
|
2021
Q3 | $276K | Sell |
16,142
-843
| -5% | -$13.1K | 0.12% | 210 |
|
|
2021
Q2 | $227K | Buy |
16,985
+12,216
| +256% | +$301K | 0.09% | 258 |
|
|
2021
Q1 | $244K | Buy |
4,769
+75
| +2% | +$4.51K | 0.1% | 295 |
|
|
2020
Q4 | $291K | Sell |
4,694
-38
| -0.8% | -$2.18K | 0.12% | 228 |
|
|
2020
Q3 | $259K | Sell |
4,732
-654
| -12% | -$35.2K | 0.14% | 254 |
|
|
2020
Q2 | $310K | Sell |
5,386
-6,061
| -53% | -$330K | 0.15% | 297 |
|
|
2020
Q1 | $460K | Sell |
11,447
-1,668
| -13% | -$70.8K | 0.19% | 179 |
|
|
2019
Q4 | $519K | Sell |
13,115
-17,171
| -57% | -$302K | 0.08% | 201 |
|
|
2019
Q3 | $205K | Sell |
30,286
-1,687
| -5% | -$12.7K | 0.04% | 249 |
|
|
2019
Q2 | $297K | Buy |
31,973
+5,521
| +21% | +$63.9K | 0.06% | 222 |
|
|
2019
Q1 | $367K | Sell |
26,452
-3,200
| -11% | -$36.6K | 0.78% | 43 |
|
|
2018
Q4 | $324K | Sell |
29,652
-7,150
| -19% | -$75.4K | 0.06% | 94 |
|
|
2018
Q3 | $465K | Sell |
36,802
-27,027
| -42% | -$326K | 0.05% | 134 |
|
|
2018
Q2 | $841K | Buy |
+63,829
| New | +$763K | 0.74% | 18 |
|
Other funds holding CCXI
Virtus ETF Advisers's CCXI Position: Q4 2022 in Review
Virtus ETF Advisers sold out of ChemoCentryx, Inc. (CCXI) in Q4 2022, closing a stake of 10,074 shares — an estimated $520K sold.
Virtus ETF Advisers first reported a position in CCXI in Q2 2018 and held it in 18 quarters. The position peaked at $841K in Q2 2018. 1 fund tracked by Wall St. Rank holds CCXI as of Q4 2022.
- Virtus ETF Advisers reported no remaining ChemoCentryx, Inc. position as of Q4 2022 after selling out during the quarter.
- Virtus ETF Advisers sold 10,074 ChemoCentryx, Inc. shares in Q4 2022, an estimated $520K.
- Virtus ETF Advisers first reported a position in ChemoCentryx, Inc. in Q2 2018 and held it in 18 quarters.
- Virtus ETF Advisers's ChemoCentryx, Inc. position peaked at $841K in Q2 2018.
- 1 fund tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2022.
Based on Virtus ETF Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.